Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

South Africa takes the lead in HIV prevention with a groundbreaking twice-a-year injection being added to the Essential Medicines List.

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...

The treatment landscape for HIV is discussed by a panel led by Dr Welch. Adam C. Welch, PharmD, MBA: Let’s get into some of those treatments. Shauna, can you provide an overview of how we treat HIV?